← Leaderboards
Namasivayam Ambalavanan
Lurie Children'S Hospital Of Chicago
$15,643,062
Attributed
$29,735,163
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,735,163 · 16
By mechanism
R01$16,300,919 · 6
U01$6,336,282 · 2
U44$3,460,586 · 1
UG1$1,389,463 · 2
U34$753,643 · 1
PL1$742,500 · 1
Top collaborators
- Pamela Donohue6 shared
- Premananda Pai Indic6 shared
- David A Kaufman6 shared
- Michael L. Terrin6 shared
- Rose Marie Viscardi6 shared
- Ken B Waites6 shared
- James S Hagood5 shared
- Naftali Kaminski5 shared
Most similar at Lurie Children'S Hospital Of Chicago
Same institution · by research overlap
- Nelson R Claure$2,554,417
- Anna Maria Hibbs$9,558,831
- Debra Ellyn Weese-Mayer$3,635,994
- Mary E Robbins$816,920
- Joseph Randall Moorman$13,667,239
Others in their field
Top investigators on “Infant”
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
- Barbara Driver · Westat, Inc.$184,782,231
- Abhik Das · Research Triangle Institute$178,442,979
- Elizabeth A Thom · George Washington University$170,837,172
- J Brooks Jackson · Social And Scientific Systems, Inc.$150,941,831
Research focus
InfantNeonatalPremature InfantBirthCohortPregnancyEnrollmentRespiratorySignal TransductionBronchopulmonary DysplasiaPostnatalOxygenResponseLungClinical ResearchProspectiveNewborn InfantResearch PersonnelMorbidity - Disease RateProgramsNational Institute Of Child Health And Human DevelopmentMulticenter Neonatal Research NetworkFutureDiagnosis
Grant awards (58)
Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age$1,587,757
R01 · FY2025 · HL
Prapela® SVS incubator pad: A cost-effective stochastic vibrotactile device to improve the clinical course of infants with apnea of prematurity.$1,475,909
U44 · FY2025 · DA
Let-7b in BPD$554,376
R01 · FY2025 · HL · contact PI
Vital Signs In Opioid-Exposed Neonates$507,733
R01 · FY2025 · HD · contact PI
UAB Clinical Site HEAL Neonatal Opioid Withdrawal Pharmacological Treatments$221,454
UG1 · FY2025 · HD · contact PI
UAB Outcomes of Babies with Opioid Exposure (OBOE study)$133,693
UG1 · FY2025 · HD · contact PI
Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age$1,485,040
R01 · FY2024 · HL
Prapela® SVS incubator pad: A cost-effective stochastic vibrotactile device to improve the clinical course of infants with apnea of prematurity.$1,484,463
U44 · FY2024 · DA
Let-7b in BPD$543,288
R01 · FY2024 · HL · contact PI
Vital Signs In Opioid-Exposed Neonates$502,655
R01 · FY2024 · HD · contact PI
UAB Clinical Site HEAL Neonatal Opioid Withdrawal Pharmacological Treatments$221,454
UG1 · FY2024 · HD · contact PI
UAB Outcomes of Babies with Opioid Exposure (OBOE study)$148,500
UG1 · FY2024 · HD · contact PI
Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age$1,521,329
R01 · FY2023 · HL
Let-7b in BPD$554,376
R01 · FY2023 · HL · contact PI
Vital Signs In Opioid-Exposed Neonates$507,733
R01 · FY2023 · HD · contact PI
Prapela® SVS incubator pad: A cost-effective stochastic vibrotactile device to improve the clinical course of infants with apnea of prematurity.$500,214
U44 · FY2023 · DA
UAB Clinical Site HEAL Neonatal Opioid Withdrawal Pharmacological Treatments$221,454
UG1 · FY2023 · HD · contact PI
Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age$1,485,619
R01 · FY2022 · HL
Vital Signs In Opioid-Exposed Neonates$507,733
R01 · FY2022 · HD · contact PI
Vital Signs In Opioid-Exposed Neonates$519,859
R01 · FY2021 · HD · contact PI
UAB Clinical Site HEAL Neonatal Opioid Withdrawal Pharmacological Treatments$442,908
UG1 · FY2021 · HD · contact PI
Pre-Vent Apnea$537,136
U01 · FY2020 · HL · contact PI
Acute Renal Injury Sequelae in NICU Graduates (ARISING)$357,148
U34 · FY2020 · DK
Pre-Vent Apnea$249,780
U01 · FY2020 · HL · contact PI
UAB Outcomes of Babies with Opioid Exposure (OBOE study)$1
RL1 · FY2020 · HD · contact PI
UAB Outcomes of Babies with Opioid Exposure (OBOE study)$742,500
PL1 · FY2019 · HD · contact PI
Pre-Vent Apnea$563,824
U01 · FY2019 · HL · contact PI
Acute Renal Injury Sequelae in NICU Graduates (ARISING)$396,495
U34 · FY2019 · DK
Alveolar DevMAP$734,685
U01 · FY2018 · HL · contact PI
Pre-Vent Apnea$564,662
U01 · FY2018 · HL · contact PI
Alveolar DevMAP$742,417
U01 · FY2017 · HL · contact PI
Pre-Vent Apnea$538,635
U01 · FY2017 · HL · contact PI
STOP BPD$367,500
R01 · FY2017 · HL · contact PI
Alveolar DevMAP$734,777
U01 · FY2016 · HL · contact PI
STOP BPD$367,500
R01 · FY2016 · HL · contact PI
Pre-Vent Apnea$195,340
U01 · FY2016 · HL · contact PI
Alveolar DevMAP$734,976
U01 · FY2015 · HL · contact PI
Azithromycin to prevent BPD in ureaplasma-infected preterms.$567,292
R01 · FY2015 · HD
STOP BPD$367,500
R01 · FY2015 · HL · contact PI
Azithromycin to prevent BPD in ureaplasma-infected preterms.$127,500
R01 · FY2015 · HD
Alveolar DevMAP$740,050
U01 · FY2014 · HL · contact PI
Azithromycin to prevent BPD in ureaplasma-infected preterms.$571,913
R01 · FY2014 · HD
Azithromycin to prevent BPD in ureaplasma-infected preterms.$570,381
R01 · FY2013 · HD
Azithromycin to prevent BPD in ureaplasma-infected preterms.$597,460
R01 · FY2012 · HD
TRANSFORMING GROWTH FACTOR - BETA MEDIATES EFFECTS OF HYPOXIA IN NEWBORN LUNG$358,875
R01 · FY2012 · HL · contact PI
Azithromycin to prevent BPD in ureaplasma-infected preterms.$622,943
R01 · FY2011 · HD
TRANSFORMING GROWTH FACTOR - BETA MEDIATES EFFECTS OF HYPOXIA IN NEWBORN LUNG$362,500
R01 · FY2011 · HL · contact PI
TRANSFORMING GROWTH FACTOR - BETA MEDIATES EFFECTS OF HYPOXIA IN NEWBORN LUNG$362,500
R01 · FY2010 · HL · contact PI
TRANSFORMING GROWTH FACTOR - BETA MEDIATES EFFECTS OF HYPOXIA IN NEWBORN LUNG$362,500
R01 · FY2009 · HL · contact PI
TRANSFORMING GROWTH FACTOR - BETA MEDIATES EFFECTS OF HYPOXIA IN NEWBORN LUNG$54,557
R01 · FY2009 · HL · contact PI
TRANSFORMING GROWTH FACTOR - BETA MEDIATES EFFECTS OF HYPOXIA IN NEWBORN LUNG$362,500
R01 · FY2008 · HL · contact PI
MMP-2 in Neonatal Hypoxic Pulmonary Vascular Remodeling$127,073
K08 · FY2008 · HD · contact PI
C-Reactive Protein in Extremely Low Birth Weight Neonates$71,050
R03 · FY2008 · HD · contact PI
MMP-2 in Neonatal Hypoxic Pulmonary Vascular Remodeling$124,279
K08 · FY2007 · HD · contact PI
C-Reactive Protein in Extremely Low Birth Weight Neonates$72,500
R03 · FY2007 · HD · contact PI
MMP-2 in Neonatal Hypoxic Pulmonary Vascular Remodeling$121,566
K08 · FY2006 · HD · contact PI
MMP-2 in Neonatal Hypoxic Pulmonary Vascular Remodeling$118,930
K08 · FY2005 · HD
MMP-2 in Neonatal Hypoxic Pulmonary Vascular Remodeling$116,371
K08 · FY2004 · HD